Michael O’Donnell is a partner in the firm’s Palo Alto office, specializing in corporate and securities law. He has more than 30 years of experience providing general corporate representation to biopharmaceutical and other life sciences companies. He offers particular expertise in venture capital financings, public offerings, mergers and acquisitions, strategic alliances, technology licensing, and corporate spin-out transactions. He represents numerous public and private biopharmaceutical, medical device, diagnostic, and instrumentation companies.
Michael was the founding attorney and lead attorney on the initial public offerings for companies such as Illumina, Neurocrine Biosciences, Cytokinetics, Cassava Sciences, Sequana Therapeutics, Ciphergen Biosystems, NeurogesX, Argonaut Technologies, and Microcide Pharmaceuticals.